Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Dec 22;8:1884. doi: 10.3389/fimmu.2017.01884

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 Obiero, Ndiaye, Sciré, Kaunyangi, Marchetti, Gone, Schütte, Riccucci, Auerbach, Saul, Martin, Bejon, Njuguna and Podda.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Percentage of participants with seroresponse* (A) and anti-Shigella sonnei LPS IgG ≥121 EU (B), by timepoint (full analysis set for immunogenicity). LPS, lipopolysaccharide; IgG, immunoglobulin G; EU, enzyme-linked immunosorbent assay units; 1.5/25 μg, 5.9/100 μg, participants who received the 1790GAHB vaccine with an O antigen/protein content of 1.5/25 and 5.9/100 μg, respectively, at days 1 and 29; Control, participants who received meningococcal vaccine against serogroups A, C, W, and Y at day 1 and tetanus, diphtheria, and acellular pertussis vaccine at day 29. Note: *Seroresponse to vaccination was defined as an increase in the anti-S. sonnei LPS serum IgG level of ≥50% for participants with baseline levels >50 EU or an increase of ≥25 EU for participants with pre-vaccination levels ≤50 EU.